Mechanistically, RPL39 and MLF2 expression was associated with iNOS signaling, and their mutations were associated with shorter median time to relapse in a cohort of 53 breast cancer patients, which suggests that iNOS inhibition represents a promising strategy for the treatment of TNBC [124]. The gene discussed is MLF2; the disease is breast carcinoma.